Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,200 shares, a decrease of 71.4% from the December 15th total of 4,200 shares. Based on an average daily trading volume, of 11,400 shares, the days-to-cover ratio is currently 0.1 days.

Scinai Immunotherapeutics Stock Performance

NASDAQ:SCNI traded up $0.02 during mid-day trading on Tuesday, hitting $3.44. The stock had a trading volume of 3,304 shares, compared to its average volume of 10,950. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $3.34 and a 200-day simple moving average of $3.61. The stock has a market capitalization of $2.93 million, a price-to-earnings ratio of -0.01 and a beta of 2.34. Scinai Immunotherapeutics has a 52 week low of $2.23 and a 52 week high of $8.92.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.